AOD-9604: The Definitive Guide

What is AOD-9604?

AOD-9604 is a manufactured peptide, a chain of 16 amino acids based on the tail end of human growth hormone, that people use in the hope of losing body fat.

Amino acids are the building blocks of proteins. Growth hormone is a large protein of 191 amino acids. AOD-9604 copies only its last 15 (positions 177 to 191) and adds one extra amino acid, tyrosine, at the front, which is why chemists write it as Tyr-hGH 177–191. Two of its amino acids are linked to close the chain into a small loop. Researchers in Australia chose this piece in the 1990s because, in animal experiments, it seemed to carry growth hormone's effect on fat without its effects on growth. [1], [2], [3], [4]

The key term is investigational. AOD-9604 was tested for weight loss, mostly as a pill, in about 900 people between 2001 and 2006. The largest trial failed, and development for obesity stopped in 2007. Since 2015 the same molecule, renamed LAT8881, has been tested for pain. It has never been approved as a medicine in any country, and it is now sold online mostly as injectable “research” vials. [5], [6], [7], [8], [9]

It is also not the same molecule as “HGH Fragment 176–191”, a name many sellers use for it. The difference is explained below.

Typical AOD-9604 Protocols

The most common protocol in the reviewed sources is 300 mcg once a day by subcutaneous injection, usually first thing in the morning before eating, for about 8–12 weeks. [11], [12], [13], [14]

Titration Changing the amount in steps

Many sources use one fixed amount and say no titration is needed. The most common stepped approach is 300 mcg a day for weeks 1–4, then 500 mcg a day for weeks 5–12. Others start with 200 mcg a day for the first 1–2 weeks, or step from 300 to 400 mcg after four weeks. [11], [15], [16], [12], [17]

Breaks and cycles

After a course, about 4 weeks off is the most common break. Other sources describe 2–4 or 4–6 weeks off, and some run the course on weekdays only (five days on, two off). [11], [18], [13], [19]

Timing When in the day

Almost every source says to inject on an empty stomach, usually first thing in the morning, and many add a wait of 30–60 minutes before eating. No study in people has tested whether timing changes the result. [11], [20]

Read the units: mcg means micrograms; 1 mg equals 1,000 mcg. These amounts refer to AOD-9604 alone, not the total weight of a blend. The human trials used swallowed doses measured in milligrams, which cannot be swapped for injected micrograms.

Each row is a complete schedule as published, so its amount and duration belong together. Low, mid and high are alternatives, not steps to move through. These schedules come from protocol sources, not clinical trials: no study has given AOD-9604 to people by subcutaneous injection. [1]

Where protocols differ: steps, breaks, fasting and other forms ↓

What is AOD-9604 commonly used for?

People look into AOD-9604 almost entirely for fat loss: losing weight, shifting fat around the belly and hips, or restarting weight loss that has stalled. Many now add it to a prescription weight-loss medicine such as semaglutide or tirzepatide. A smaller group uses it for joint pain, based on animal research.

Fat loss is also the one use properly tested in people, because that is what AOD-9604 was developed for.

Weight loss and fat loss

The hope is simple: help the body burn stored fat without the side effects of growth hormone itself. In obese mice and rats, AOD-9604 reduced weight gain and increased fat burning. [4], [21]

In people, it did not hold up. In a 12-week trial, 300 adults with obesity enrolled and 283 started treatment. The best group (1 mg a day, swallowed) lost 2.8 kg compared with 0.8 kg on placebo. But the trial's planned comparison found no statistically clear difference at any of the five doses, and higher doses did no better than the lowest. A larger 24-week trial of 502 adults then found that no dose produced even 1 kg more weight loss than placebo, and the company stopped developing it for obesity. [22], [6]

Doserly

What did the weight-loss trials find?

12-week trial · 2004 · swallowed capsules · 283 adults started

Placebo −0.8 kg; 1 mg a day −2.8 kg; 5 mg a day −1.6 kg; 10 mg a day −1.0 kg; 20 mg a day −1.7 kg; 30 mg a day −2.2 kg. No dose beat placebo on the trial's planned week-12 comparison (best: 1 mg, p = 0.10). Higher doses did no better than the lowest. Kilograms of body-weight change at week 12 (adjusted group means as reported by the sponsor; its standard errors are not shown).

24-week trial (OPTIONS) · 2005–2007 · swallowed tablets · 502 adults randomized

0.25, 0.5 or 1 mg a day, plus a supervised diet and exercise program. Less than 1 kg more weight loss than placebo at every dose. Main goal not met · development for obesity stopped in February 2007.

The best 12-week result was 2 kg more than placebo and not statistically clear; the larger, longer trial found under 1 kg.

These trials used swallowed capsules and tablets. People now use subcutaneous injections, a route never tested in people; the idea that these injections would succeed where pills failed is a guess, not a finding. [1]

Breaking a weight-loss plateau on a GLP-1 medicine

The most common story today is about adding AOD-9604 when weight loss slows on a GLP-1 medicine such as semaglutide, tirzepatide or retatrutide. Some people describe the plateau ending or their waist shrinking after they added it. Others notice nothing extra. [23], [24]

Because these medicines cause substantial weight loss on their own, a plateau that ends while someone is taking both cannot tell us which one did it. No study has tested AOD-9604 together with a GLP-1 medicine. The experience section follows several of these accounts.

Belly fat and “inches, not pounds”

Many sellers and users say AOD-9604 targets belly or visceral fat (fat deep inside the abdomen), so the tape measure changes before the scale does. No human study has shown that it acts on one area of the body more than another. In the 12-week trial, the company reported only trends toward smaller waists and less abdominal fat on scans, without statistical tests, and the 24-week trial reported no relevant findings on its other measures. [22], [6]

Joints and cartilage

Some courses and clinics promote AOD-9604 for knee osteoarthritis (wear-and-tear arthritis) or cartilage repair. The evidence is one rabbit study: after a chemical injury to the knee, weekly injections of 0.25 mg into the joint for four weeks led to less cartilage damage and a shorter period of limping. Adding hyaluronic acid, a common joint injection, worked best. No study has tested joint outcomes in people, or tested subcutaneous injections for joints. [25], [26]

Other uses you may come across

Claims about bone, pain relief, skin and infection come from rat theses, mouse studies or the later pain program, whose three human trials found no benefit. Its use in cosmetic creams is not evidence that it works through the skin. [27], [28], [29], [30]

See the human study results or explore the supporting animal research.

Where do AOD-9604 protocols differ?

The 300 mcg amount is easy to find. The details around it vary: splitting, stepping up, time on and off, and food timing.

Is the number for one dose or the whole day?

250 mcg twice daily means 500 mcg for the day, almost twice the common 300 mcg once-daily total. Some pages list 300 mcg once daily and 250 mcg twice daily side by side as if they were equivalent. They are not. The table above keeps the amount each time and the daily total in separate columns for that reason. [31], [32]

Once daily, twice daily or weekdays only?

Once daily appears in almost every source. About a third also offer a split, such as 250 mcg in the morning and 250 mcg before bed, and a few use weekdays only (one page gives 240 mcg Monday to Friday). Splitting has not been shown to work better. [33], [19], [13]

Community education groups describe the same core pattern: 300 mcg first thing in the morning, most often five days on and two off.

Do sources start low or step up?

Many use a fixed amount; others step from 300 to 500 mcg after four weeks, start at 200 mcg, or move from 300 to 400 mcg. There is no evidence that a higher amount works when a lower one did not; in the 12-week pill trial, higher doses did no better than the lowest. [15], [12], [17], [22]

How many weeks, and what happens between courses?

A course is the period of repeated use; a cycle is the course plus a planned break. The most common course length is 8–12 weeks, followed by 8–16 weeks. Across all pages, courses range from 2 weeks to 6 months. [10], [11], [31], [34]

Breaks vary from one week to two months, with about 4 weeks the most common. Community education groups usually describe 8–12 weeks on and 4–8 weeks off, though some teach that no break is needed. No study has tested whether breaks matter. [11], [32], [34]

Does it have to be taken on an empty stomach?

Nearly every source insists on it, and many add exercise soon afterwards. The reasoning is that insulin released after a meal slows the release of stored fat. That is a reasonable idea, but it has never been tested with AOD-9604 in people: the trials did not compare fasted and fed dosing. [11], [35], [19], [22]

Where do the sources disagree most?

The widest gap is the daily amount: the common range is 250–500 mcg, but one clinic page lists up to 1,000 mcg a day. A higher listed amount is not a tested safe upper limit. [10], [36]

Pages also contain factual errors. Some describe the swallowed trial doses as injections, cite federal “GRAS” reference numbers that belong to pea fiber and a stevia sweetener, or say AOD-9604 is not banned in sport. Check any study a page cites before trusting the protocol built on it. [37], [36], [38], [39], [40]

Do capsules, creams and nasal sprays use the same amounts?

No, and none of these products has been tested at the amounts sold. Capsules and dissolving tablets are labeled at 300–1,000 mcg a day. Creams are labeled at 0.5–1 mg per application. One nasal spray lists only its strength per millilitre, so the amount per spray cannot be worked out. Many pages also quote the 1 mg daily pill dose from the old trials, which is a trial dose, not a tested protocol for these products. [41], [34], [42]

Compare swallowed, injected and IV AOD-9604. The protocol table at the top covers subcutaneous injection only.

What about blends and stacks?

The best-known blend adds CJC-1295 and ipamorelin, two peptides that make the body release more growth hormone. One 12 mg vial holds 6 mg of AOD-9604 and 3 mg of each other peptide, with AOD-9604 stepped from 200 to 400 mcg a day. The vial's total weight is not its AOD-9604 content. [43]

Community education groups also often pair AOD-9604 with L-carnitine, a nutrient that helps carry fatty acids into the parts of cells that burn them. No study has tested either combination. Read the Doserly guides to CJC-1295, ipamorelin and L-carnitine.

How do micrograms convert to syringe units?

Many people meet “units” on an insulin syringe. A U-100 syringe has 100 units per millilitre, so units measure volume, not an amount of AOD-9604. How much AOD-9604 each unit holds depends on how much liquid was added to the vial.

For example, 5 mg (5,000 mcg) mixed into 2 mL gives 2,500 mcg per mL, or 25 mcg per unit, so 300 mcg is 12 units. The same vial mixed into 3 mL gives about 16.7 mcg per unit, so 300 mcg becomes 18 units. A number of units copied from someone else's protocol can therefore be wrong. Doserly's reconstitution calculator works this out for any vial and shows each step.

What happens when you stop AOD-9604?

Very little is known. One trial reported four weeks of weight results after the last dose; no study has looked for withdrawal symptoms or followed weight for longer. The lack of reports is a gap in the evidence, not proof that nothing happens. [22], [5]

• The 12-week pill trial. People returned 1, 4 and 12 weeks after their last dose. The company's analysis covered only the first four weeks and reported “no evidence of rebound weight gain” compared with placebo. We found no report of the 12-week follow-up visit. [22]
• The 24-week trial checked safety for four weeks after the last tablet, but its published weight results end with treatment. [50], [5]
• The later pain trials followed people for one to two weeks after the last dose, and the nerve-pain trial had a two-week break between its treatment periods. Their posted results list no serious adverse events, but they do not report what happened during the breaks separately. [7], [54], [51], [104]
• Community accounts point both ways. One person said their progress “definitely slows” when they pause daily injections. Another thought a body-fat scale showed faster fat loss, then saw the same trend continue after stopping and called it “a fluke”. A third noticed no difference when they restarted after two months off. Two of the three were also taking tirzepatide, a GLP-1 medicine. [23], [90], [81]

Do swallowed, injected and IV AOD-9604 behave the same way?

An oral dose is swallowed, so it meets digestion and the gut wall before any of it reaches the blood. An intravenous (IV) dose goes straight into a vein. A subcutaneous injection goes into the fatty layer under the skin and is absorbed from there. These are different exposures, not interchangeable versions of the same experiment.

Doserly

Which routes have been tested in people?

Oral (swallowed)

Tested in people. 6 trials · 0.25–60 mg a day · up to 24 weeks · no meaningful weight loss in the obesity trials.

Intravenous (IV, into a vein)

Tested in people. 3 trials · one-off infusions, not daily use.

Subcutaneous injection

Not tested in people. The route protocol websites describe: usually 250–500 mcg a day.

Cream (through the skin)

Not tested in people. Sold as a cosmetic ingredient; no human absorption data.

Nasal

Animal study only. Mice with influenza, for a different purpose.

Into a joint (intra-articular)

Animal study only. Rabbits with knee injury, 0.25 mg weekly for 4 weeks.

The route most people use today is one that has never been tested in people.

All nine human trials used swallowed or IV doses. The US Food and Drug Administration (FDA) reviewed the evidence in 2024 and found no human information on subcutaneous or skin use, the ways it is sold today, and nasal delivery has been tested only in mice with influenza. [1], [5], [29]

Bioavailability describes how much of a dose reaches the blood in the form being measured. For swallowed AOD-9604 it is unknown. In a pig study, the calculated oral figure came out at 170%, which FDA noted is impossible, so the true value remains unclear. [1], [45]

How long does AOD-9604 last in the body?

Not long, as far as anyone has measured. Half-life is the time it takes for the level in the blood to fall by half. In pigs given an IV dose it was about 3 minutes, and in rat blood in a test tube the peptide was broken down within an hour. [1]

In people, the only measurements come from IV infusions in the later pain program. Blood levels peaked about 5 minutes after the infusion, and the company's conference poster reports a half-life of less than 30 minutes. That poster has not been peer reviewed, and nobody has measured levels after a subcutaneous injection. [46], [47]

A short half-life does not by itself mean a short effect: the body breaks AOD-9604 into smaller pieces, and at least one is active in the pain research. How long any effect on fat lasts has not been measured. [48], [47]

Should it be injected into belly fat or near a sore joint?

No study has compared injection sites in people. Protocol pages usually suggest the abdomen, and some community education materials teach injecting near a painful joint. The rabbit cartilage study injected into the joint itself (intra-articular), which is a different route from a subcutaneous injection nearby. [11], [25]

How should AOD-9604 be stored, and how long does it last?

We found no published stability study of the vials people buy, so there is no tested use-by time for mixed AOD-9604. What exists are supplier data for the raw powder, the developer's tests of capsules and advice on protocol pages. [1]

• Powder, before mixing. Supplier documents quoted by FDA in 2024 give about 3 years at −18 °C, 1 year at 0–7 °C and 6 months at 7–30 °C for the plain (free base) powder, kept dry in a closed container. For the acetate salt form, they recommend 2–8 °C for up to six months and −20 °C for longer. These are the suppliers' figures, not FDA's own tests. [1]
• After mixing. No tested use-by time has been published. Protocol pages say to keep the mixed (reconstituted) vial in a fridge at 2–8 °C, but their use-within times range from 2–4 weeks to 30–60 days, and none cites a stability test of AOD-9604. Most also say not to freeze the mixed solution and to protect it from light. [34], [37], [20], [12], [36]
• Heat and moisture. The developer's patent reports that an early dry capsule formulation, made with freeze-dried AOD-9604, lost stability at room temperature within about three months, and that adding the amino acid arginine made its capsules more stable. The later trial capsules contained arginine and were kept in a fridge, at the clinic and at home. [105], [7]
• Cloudy or gelled vials. FDA notes that peptides like AOD-9604 are sensitive to heat, acidity and concentration, and can clump together (aggregate), especially during storage. Clumping can reduce activity and make immune reactions more likely. FDA inspectors recorded complaints of particles floating in a compounded AOD-9604 injection a few days after mixing. Some protocol pages say not to use a cloudy or discolored solution, and people in public forums describe vials that gel. [1], [60], [37], [42], [106]

This guide does not cover mixing or injection technique; the Academy note below covers practical handling.

What do we actually know about AOD-9604 in people?

More than for most peptides sold online: six company trials with about 900 people, and three later trials in pain. That record gives a fairly clear answer on weight loss from swallowed doses, and almost no answer on anything else. Each was a controlled trial, comparing people given the drug with similar people given a placebo.

What did the weight-loss trials find?

The six company trials involved about 900 people in total; published counts range from 893 to 936. [5], [7]

Why was the 12-week trial called a success?

When the results came out in December 2004, the company's announcement was headlined as a successful trial. Its own appendix tells a more careful story. The comparison planned before the trial (weight at week 12 for each dose against placebo) was not statistically clear for any dose. Only a second analysis, of how fast weight changed over the weeks, favored three of the doses. [22]

There was also no dose pattern (1 mg did best, 10 mg worst), about one in five people who started did not finish (only 228 of 283 did), and the results were never published in a peer-reviewed journal. The 24-week trial that followed was larger, longer and publicly registered, and it did not confirm the result. [22], [6]

Numbers such as “2.6 kg compared with 0.8 kg” that circulate online do not match the company's results table, which reported 2.8 kg.

Did it work better in women?

The company said the 1 mg result reached statistical significance in women in the 12-week trial, and, after the 24-week trial failed, pointed to a group of 149 women who had lost less than 2 kg during the starting period. Sex and early diet response were planned in advance as secondary subgroups, but the 149 women combined both, and neither result changed the failed main comparison. Checking several subgroups can produce a favorable-looking result by chance, so this is a lead to test, not a finding. [6]

What did the later pain trials find?

From 2019 the same molecule, as LAT8881, was tested in three small trials: 53 people with nerve pain took 30 mg by mouth twice a day for four weeks; 21 people with migraine took 60 mg at the start of an attack; and people with lower-back nerve pain received a single IV infusion. None of the three found less pain than placebo on its main measure, and none reported serious adverse events. [28], [51], [46]

Where were the results published?

Mostly in company documents. The only journal paper on the six obesity trials is a safety report written mainly by company staff, in a journal that is not indexed in MEDLINE, the main medical database. The weight results appear only in company announcements and a conference abstract. FDA reviewed all of this in 2024 and concluded there was a “lack of evidence” that it works for obesity by any route. [5], [52], [1]

What would a meaningful result look like?

In the 24-week trial, people on placebo who followed the diet and exercise program lost weight too; AOD-9604 added less than 1 kg on top. That gap, not the total lost, is the drug's effect. The same applies to a personal experience: if a GLP-1 dose, calories or training changed at the same time, the scale cannot say which change did the work. [6]

How might AOD-9604 work?

The research on how it works comes from rats, mice and cells, mostly from the laboratory that discovered it. It explains why the idea looked promising; the human trials are the better guide to what it does in people.

What did the animal studies show?

In the early 1990s, researchers found that the 177–191 piece of growth hormone reduced fat-making in rat fat tissue, though it did not clearly speed up fat breakdown in that test. In obese mice, it reduced weight gain and fat mass. [3], [56]

AOD-9604 itself, given by mouth to obese rats for 19 days, cut their weight gain by more than half (15.8 g versus 35.6 g) without harming their response to insulin. Given for 14 days to obese mice, it reduced weight gain and increased fat burning and glycerol, a marker of fat breakdown (lipolysis). [21], [4]

These studies measured slower weight gain in growing animals, not weight lost by adults. Nobody has shown why the effect did not carry over to the human trials.

Does it act like growth hormone?

Not in the ways that were tested. In cells, AOD-9604 did not attach to the growth hormone receptor and did not make cells multiply, unlike growth hormone. In mice it did not raise blood sugar, which growth hormone can. In the human trials it did not raise IGF-1, the growth factor that growth hormone increases, and no antibodies against it were found in the people tested. [4], [22], [5]

So it is not a way to raise growth hormone and not a substitute for it. Whether pairing it with peptides that do release growth hormone adds anything has not been tested.

Does it work through beta-3 receptors?

Partly, in mice. Beta-3 receptors on fat cells respond to adrenaline and help release stored fat. In mice bred without them, two weeks of AOD-9604 no longer changed body weight or fat breakdown, but a single dose still increased fat burning. The authors concluded AOD-9604 does not act directly on the receptor, though it increased the receptor's gene activity in fat tissue. [57]

FDA noted in 2024 that its actual molecular target is unknown. In 2026, researchers working on the pain program reported that one of its breakdown products binds a protein called LanCL1 in the spinal cord of rodents. That finding concerns pain, not fat. [1], [58]

What are the risks and unanswered questions?

Is AOD-9604 safe?

Its safety as it is used today has not been established. In the company trials, swallowed doses for up to 24 weeks caused side effects at rates similar to placebo, and the IV studies found a few notable events. But nobody has studied subcutaneous injections, use beyond 24 weeks or combinations with other drugs, and the products sold online are not the ones tested. [5], [1]

In the 24-week trial, 83% of people on placebo and about 79% of all participants reported at least one adverse event, with serious events in every group, including placebo. That is reassurance about swallowed doses of 0.25–1 mg, not about 300 mcg injected every morning for months. [5]

What side effects were reported in the trials?

• IV infusions: headache was common, and one man had severe chest tightness judged possibly related. Five of 23 men reported euphoria (an unusually elevated mood) after active infusions and none after placebo, starting 21 hours to 4 days later and lasting 1.5 hours to 7 days. [5], [49]
• Swallowed doses: at the highest doses (about 54 mg), people had more headache, diarrhea and gas, and one person had serious diarrhea judged possibly related. [5], [49]
• The 12-week trial: five serious events were reported: four cancers (basal cell and squamous cell skin cancers, a melanoma and a breast cancer) and a benign fatty lump (lipoma). Investigators judged none related to AOD-9604; FDA later listed them among its concerns. [5], [1]
• The later IV pain study: at the highest dose, 2 of 6 volunteers had side effects judged related, including numbness, nausea, flushing, a fast heartbeat, an unpleasant mood and chest discomfort. [46]

FDA's adverse-event databases held no reports for AOD-9604 in its 2024 search. FDA added that the absence of reports does not mean a substance is safe. [1]

What did animal safety studies find?

The company's safety paper concluded there was no evidence of toxic or genetic-damage concerns. FDA read the same data in 2024 and saw possible signals: changes in a bone-turnover marker in rats, changes in liver cells in all high-dose female monkeys, and genetic-damage tests with unclear results. There are no reproduction studies and no carcinogenicity studies. [45], [1]

Could product quality change the risk?

Yes. In a 2018 Belgian study, three vials of AOD-9604 bought online as “research chemicals” were 45.9%, 4.8% and 4.8% pure, and their peptide content ranged from 28% to 183% of the average. The most common impurity was a broken version of the peptide's loop. [59]

Cloudiness and clumping are a known problem. FDA inspectors recorded complaints of particles floating in a compounded AOD-9604 injection a few days after mixing, confirmed across several batches, and a compounded AOD-9604 injection was recalled in 2021 because its sterility could not be assured. FDA lists aggregation (peptide molecules clumping together) and impurities among its concerns, because they can make immune reactions more likely, especially with injections. [60], [61], [62]

Is AOD-9604 legal to buy? Is it FDA-approved?

Checked September 23, 2026. Rules differ by country and change quickly.

United States. AOD-9604 is not an FDA-approved medicine and has never been a component of one. The recent steps:

• 2020 and 2022. FDA warning letters to compounding pharmacies named AOD-9604 among ingredients they were not permitted to use, and one pharmacy had recalled a compounded AOD-9604 injection in July 2021. [63], [61]
• December 2024. FDA staff recommended against adding AOD-9604 to the list of ingredients pharmacies may use to prepare custom medicines (compounding). The advisory committee agreed, voting 0 to 12. [1], [64], [65]
• 2026. FDA's safety-risk page lists AOD-9604 among withdrawn nominations and notes serious adverse events that “may be associated” with it, though cause is unclear. It was not on the official list of ingredients pharmacies may compound from when checked on September 23, 2026. [62], [66]

Canada. Health Canada has not authorized AOD-9604. Advisories in August and December 2025 list it among unauthorized injectable peptides seized from sellers. [9], [67]

Australia. AOD-9604 has been a prescription-only (Schedule 4) substance since 1 June 2015, and possessing it without authority is illegal. The regulator's reason: the limited safety data “do not provide evidence that repeated intravenous or subcutaneous injections are safe.” [68], [69]

New Zealand. It has been classified as a prescription medicine since 2016. [70]

A “research use only” label does not make a product legal to sell for human use, or safe.

What about “GRAS” and “FDA GRAS status”?

That claim is misleading. GRAS (“generally recognized as safe”) is a US food-ingredient category. In June 2012 the company announced that a panel it hired had reached a “self-affirmed”, conditional GRAS conclusion for food use at up to 1 mg a day, with full effect depending on publication of its safety studies. FDA did not issue a GRAS decision, and we found no FDA GRAS notice for AOD-9604. The reference numbers some pages cite belong to pea fiber and a stevia sweetener. A food status would not cover injections in any case. [71], [38], [39]

Is AOD-9604 banned in sport? Does it show up on a drug test?

Yes, it is banned. The World Anti-Doping Agency names AOD-9604 as a growth hormone fragment in section S2 of its 2026 list, prohibited in and out of competition, and the 2027 list keeps it. WADA first confirmed it was prohibited in April 2013. [44], [72], [8]

That year, league charges against the Essendon football club alleged AOD-9604 creams and injections in its 2012 supplements program; no individual player violation was attributed to AOD-9604. [73], [74]

Anti-doping laboratories have published tests that find AOD-9604 and its breakdown products in urine. A 2013 paper reports that it does not affect the growth hormone blood test used in sport, so that test is not the way to detect it. A 2026 laboratory study found it was extensively broken down after one week in liquid serum and plasma kept in a fridge or at room temperature, while it remained detectable in dried blood spots throughout the study. How long it can be detected after someone uses it has not been published. [48], [75], [76]

Does AOD-9604 cause cancer?

Nobody knows. There are no long-term cancer studies in animals and no long-term human data. The four cancers in the 12-week trial were judged unrelated by the investigators, but a 12-week trial cannot settle the question, and FDA listed them as a concern. Unlike growth hormone, AOD-9604 did not raise IGF-1 in the trials; that removes one theoretical worry without proving there is no risk. [1], [5]

Who should be especially cautious?

These groups have no safety data in people. That is a reason for caution, not proof of harm.

• Pregnancy and breastfeeding. There are no human data and no animal reproduction studies. [1]
• A history of cancer. Because of the unresolved tumour reports and the absence of long-term studies. [1]
• Under 18. No studies include young people. This guide is written for adults.
• Competitive athletes. It is banned at all times. [44]
• People with past reactions to injected peptides. One public account describes a severe allergic-type reaction to a new vial after earlier use without problems. [77]
• People taking other medicines, including GLP-1 medicines. Interactions have not been studied; see the next question.

Has AOD-9604 been tested alongside other medicines?

Not in people. No study reports how it interacts with GLP-1 medicines, diabetes drugs, other peptides or anything else. FDA found clinics marketing it combined with other ingredients, such as aminophylline, a form of BPC-157, topiramate or naltrexone, none of which has been tested as a combination. Bring a complete list of everything you take to a pharmacist or doctor. [1]

What should be monitored while using AOD-9604?

There is no official monitoring plan, because AOD-9604 is not an approved medicine and has no prescribing label. What exists is a record of what the trials measured and the safety questions FDA raised. It can help you prepare questions for a clinician; it is not a personal testing plan. [1]

What did the trials check?

• In all six weight-loss program trials, researchers did physical examinations, recorded vital signs (blood pressure, pulse and temperature), took ECGs and ran standard blood and urine tests (blood counts, blood chemistry, urine tests and blood fats) before and after treatment. The company's published summary reports no clinically significant changes, but FDA noted that it gave no detailed laboratory values, and a later company protocol mentions some abnormal ECG recordings in the 12-week trial, with no dose pattern and judged mild and unrelated where assessed. [5], [1], [104]
• Because AOD-9604 comes from growth hormone, the multi-day trials watched for growth hormone's known effects: IGF-1, fasting blood sugar and insulin, and an oral glucose tolerance test (in the 24-week trial, at the start and after 12 and 24 weeks). They also tested blood for antibodies against AOD-9604. The trials reported no significant differences in these measures, and no antibodies were found in the people tested. [5]
• Weight-loss outcomes were body weight and waist size, plus abdominal CT scans (detailed X-ray images) in the 12-week trial and planned body-composition scans (dual-energy X-ray absorptiometry, or DEXA) in the 24-week trial. [22], [50]
• The later pain trials repeated the blood, urine, ECG and vital-sign checks, and measured drug levels in the blood for several hours after dosing. [7], [104]

Which signals matter, and why?

The liver and bone findings come from animals dosed by mouth for months, and the heart and mood reports from IV infusions. None has been tested with subcutaneous injections; they show what researchers flagged, not what a person will experience. A GLP-1 medicine taken alongside has its own label checks, which a prescriber can explain. [6], [1], [45], [5], [46], [107]

What do people in public communities report?

Public discussions of AOD-9604 are mixed, and almost all of them come from people taking something else at the same time, usually a GLP-1 medicine. The most useful accounts say what else was going on and come back with an update. [78], [23]

What do the positive reports look like?

Most describe a stalled weight loss restarting or a smaller waist. One person taking 250 mcg twice a day reported losing 12 inches across 11 measured body sites in eight weeks, versus 6 inches in the eight weeks before, while also on the highest tirzepatide dose, starting retatrutide and lifting weights. [23]

Another person added 500 mcg a day about six weeks into tirzepatide and felt it added about half a pound a week to their loss. A third reported losing 15 pounds and 2 inches over three months while also taking semaglutide. [79], [80]

Community education groups describe the same two stories most often: it “breaks a stall” on a GLP-1 medicine, and it changes “inches, not pounds”. Few of these accounts include measurements, and many began AOD-9604 at the same time as other changes.

How long did those changes last?

The follow-ups often change the picture. One person felt it added about 0.2 pounds a week in the first month, then noticed no difference afterwards, including when they restarted it. Another said it helped at first but “stopped helping after two months”. [81], [82]

Timelines also run the other way. One person noticed nothing for three weeks and then lost weight steadily, alongside semaglutide, exercise and diet changes. Another said it took three to four months before they noticed anything. These accounts cannot give an average time to results. [83], [84]

Does everyone notice a difference?

No, and non-response is common. One person used it on its own for three months “and saw no results”. Another used it every morning for six weeks with a calorie deficit and regular exercise and saw no extra change in weight, waist or body composition. Another saw nothing at 42 days, and a reply in the same thread said it “didn't do anything” before GLP-1 medicines were popular. Community education groups have only a handful of reports of using it alone, split between small changes and none. [85], [86], [24]

In community education groups, AOD-9604 is among the peptides members most often say they stopped using or consider overrated, and one widely shared view is that it is a small nudge rather than a fat-loss drug on its own.

What about unwanted effects?

The most common complaint is stinging or burning at the injection site, which some link to the acid sometimes added when mixing the powder. Others describe itchy, raised bumps where they injected. [87], [77]

A few accounts describe more: poor sleep, marked sleepiness, a mild headache after restarting, and one severe allergic-type reaction needing emergency treatment after switching to a new vial. That person also reported earlier reactions to other peptides. [88], [89], [90], [77]

Community education groups describe similar problems, along with occasional flu-like symptoms, flushing, loose stools or worse tinnitus; their most frequent practical complaint is vials that turn cloudy or gel after mixing. These reports cannot show how often an effect occurs or what caused it. See the risks section.

How can you judge a fat-loss story?

Ask what else changed at the same time (a GLP-1 dose, calories, training), how the change was measured and whether there was an update weeks later. One person who first thought a body-fat scale showed faster fat loss later called it “a fluke” when the trend continued after stopping. [90]

Also check who is telling the story. One detailed forum log of a cream containing AOD-9604 reported losing about half an inch from the waist and 6 pounds over roughly six weeks, but the writer received the product free, posted discount codes and then added another compound. [91]

These selected discussions are not a survey of all users, a response rate or a substitute for the controlled trials.

How does AOD-9604 compare with tesamorelin, semaglutide and other fat-loss compounds?

These compounds are often discussed alongside AOD-9604 for fat loss. We found no study comparing any of them directly with AOD-9604, or testing AOD-9604 together with a GLP-1 medicine, so the table compares what each one is and what is known in people. The trials measured different things in different people, so their numbers cannot be ranked against each other.

The real differences are in how they act and how much is proven. Tesamorelin works through the growth hormone system and raises IGF-1, and its label asks prescribers to monitor IGF-1; AOD-9604 was designed to avoid that and did not raise IGF-1 in its trials. Semaglutide is the only one of the five with large proven weight loss in people. AOD-9604 is the only research compound here that reached large human trials, and those did not show a meaningful benefit. Each guide covers its own doses, risks and legal status. [108], [5], [109], [6]

Common questions about AOD-9604

Is AOD-9604 the same as HGH Fragment 176–191?

No. AOD-9604 starts with tyrosine and copies growth hormone positions 177–191. “HGH Fragment 176–191” starts with phenylalanine, the amino acid at position 176 of growth hormone. They differ by one building block, so they are different molecules, and the human trials tested only AOD-9604. Sellers and even a 2026 review use the names interchangeably; the anti-doping list names both separately. [2], [92], [93], [44] See what AOD-9604 is.

How long does AOD-9604 take to work?

There is no established timeline, because the human trials did not show a reliable effect. Personal reports range from a change within weeks, to three or four months, to nothing at all, usually alongside other treatments. Protocol sources usually describe courses of 8–12 weeks. [22], [84], [86], [10] See how reports changed over time.

Can you take AOD-9604 with semaglutide, tirzepatide or retatrutide?

People do, and it is the most common way it is used today, but the combination has never been studied. There are no data on whether it adds to the weight loss from a GLP-1 medicine or changes its side effects. Because these medicines work well on their own, a personal result on both cannot show what AOD-9604 contributed. [1], [23] Read the Doserly guides to semaglutide, tirzepatide and retatrutide.

Does AOD-9604 raise growth hormone or IGF-1?

No. It does not attach to the growth hormone receptor, no study has shown that it makes the body release more growth hormone, and IGF-1 did not change in the trials. Claims that it “raises growth hormone at night” are not supported; one 2026 review groups it with growth hormone-releasing peptides, which conflicts with the trial data. [4], [22], [94] See how it might work.

Do you have to take AOD-9604 on an empty stomach?

Nearly every protocol source says so, but it has never been tested. The idea is that insulin after a meal slows the release of stored fat. No study has compared fasted with fed use, so claims that it “only works fasted” are a theory, not a finding. [11], [22] See where protocols differ.

Does AOD-9604 help joints or cartilage?

The only evidence is from animals and lab experiments. In rabbits with an injured knee, weekly injections into the joint reduced cartilage damage, especially with hyaluronic acid. In a company experiment, it had no effect on intact cartilage samples. Nobody has tested joint pain, function or cartilage in people. [25], [26] See joints and cartilage.

Glossary

Plain explanations of the route, dosing and research terms used in this guide. Underlined terms in the text link here.

Adverse event

A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.

Aggregation

Peptide molecules clumping together in a solution. Clumps can make a product cloudy and can make immune reactions more likely.

Amino acid

A small chemical building block. Chains of amino acids make up peptides and proteins.

Animal study

Research in animals such as rats or mice. It shows what a substance does in a living body, but results in people can differ.

Beta-3 receptor

A receptor on fat cells that responds to adrenaline and helps release stored fat. Some sellers claim AOD-9604 works through it; mouse studies suggest the picture is more complicated.

Bioavailability

How much of a dose reaches the bloodstream in a usable form. It depends heavily on the route.

Blend

A product that combines AOD-9604 with other compounds, such as CJC-1295 and ipamorelin. The blend's total amount is not its AOD-9604 amount.

Carcinogenicity study

A long-term animal study designed to detect whether a substance can cause cancer. None has been published for AOD-9604.

Cell study (in vitro)

Research on cells grown in a dish. It gives early clues about biology, but it is far from proof of benefit in people.

Compounding

When a pharmacy prepares a customized medicine from individual ingredients. In the US, federal lists control which bulk ingredients pharmacies may use.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

Course and cycle

A course is the period of repeated use, such as 12 weeks. A cycle is a course plus a planned break before any further use.

Daily total

All the amounts given in one day, added together. For example, 250 mcg twice daily is a 500 mcg daily total.

Dose (amount each time)

The amount given on one occasion. A protocol lists both the dose and how often it is given.

ECG (electrocardiogram)

A quick, painless recording of the heart's electrical activity through stickers placed on the skin. The AOD-9604 trials took ECGs before and after treatment.

GLP-1 medicine

A prescription medicine, such as semaglutide or tirzepatide, that copies glucagon-like peptide-1 (GLP-1), a gut hormone, to reduce appetite and lower blood sugar. Retatrutide is a related drug still in trials.

GRAS

“Generally recognized as safe”, a US category for food ingredients. It does not apply to injected products and is not a drug approval.

Growth hormone

A 191-amino-acid protein made by the pituitary gland that affects growth, muscle and fat. AOD-9604 copies a short piece of it.

Half-life

The time it takes for the measured level of a substance in the blood to fall by half. It is not the same as how long an effect lasts.

IGF-1

Insulin-like growth factor 1, a growth signal the liver makes in response to growth hormone. AOD-9604 did not raise it in trials.

Intra-articular

Injected into the space inside a joint, such as the knee.

Intravenous (IV)

Given directly into a vein, so it enters the bloodstream immediately.

Investigational

Still being studied and not approved by a regulator, such as the FDA, to treat any condition.

Lipolysis

The breakdown of stored fat into fatty acids and glycerol, which the body can then burn.

Freeze-dried (lyophilized)

Dried by freezing and removing the water, leaving a powder. Most AOD-9604 is sold this way and mixed with liquid before injection.

mcg and mg

Micrograms and milligrams. 1 mg equals 1,000 mcg. Injected AOD-9604 amounts are usually written in mcg; the pill trials used mg.

Oral

Taken by mouth, as a capsule, tablet or liquid.

Oral glucose tolerance test

A blood test of how well the body handles sugar: blood sugar is measured before and 2 hours after a sugary drink. The AOD-9604 trials also measured insulin, to look for growth hormone-like effects.

Osteoarthritis

Wear-and-tear arthritis, in which the cartilage cushioning a joint gradually breaks down.

Peptide

A short chain of amino acids. AOD-9604 is a chain of 16.

Pharmacokinetics

How the body absorbs, moves, breaks down and removes a substance.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Preclinical research

Studies done before research in people: cell studies and animal studies.

Reconstitution

Mixing a freeze-dried powder with a sterile liquid so it can be measured and injected. How long mixed AOD-9604 stays usable has not been tested.

Research use only

A label on products sold for laboratory research. It does not mean a product is approved, tested for human use or legal to sell as a medicine.

Schedule 4 (Australia)

Australia's prescription-only medicine category. AOD-9604 has been listed there since 1 June 2015.

Statistically significant

A result unlikely to be explained by chance alone, judged by a test planned in advance. A difference that is not significant may simply be noise.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. This is the route most AOD-9604 protocol descriptions use, although it has not been studied in people.

Subgroup analysis

Looking at results for part of a trial's participants, such as women only. Subgroups picked after the results are known often produce chance findings.

Syringe units

Markings on an insulin syringe that measure volume. On a U-100 syringe, 100 units equal 1 mL. The amount of drug per unit depends on the vial's concentration.

Titration

Adjusting a dose in steps, usually starting lower and increasing if needed.

Visceral fat

Fat stored deep inside the abdomen around the organs, as opposed to subcutaneous fat just under the skin.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport.

Withdrawal and rebound

Withdrawal effects are symptoms caused by stopping a substance. A rebound is a problem returning after stopping, such as regaining lost weight. One AOD-9604 trial reported four weeks of weight results after stopping; withdrawal has not been studied.

Explore more of the research

Go deeper into the experiments behind the claims.

Across this guide, the citations include 24 original scientific papers: 16 preclinical papers, one human safety report and four laboratory testing papers about AOD-9604, plus three papers on other compounds cited in the comparison table, and three unpublished university theses. The optional library below groups the animal and cell work by question. Most of the fat-metabolism papers come from one university group, and some studies used AOD9401, a close relative without the extra tyrosine. Registry records, reviews, websites and personal accounts are counted separately.

In the route details, intraperitoneal means into the abdominal cavity, and intranasal means sprayed or dropped into the nose.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: published scientific studies, trial registry records, company trial reports, regulatory documents and published protocol descriptions. We also reviewed public online forums and community education groups where people describe their own experiences with AOD-9604.

The guide cites 113 sources, including 24 original scientific papers. Each type of source answers a different question. Studies show what researchers measured. Protocol descriptions show how AOD-9604 is typically used. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources